Special Issue "Botulinum Toxins: An Application in Humans and Animals"
Deadline for manuscript submissions: closed (31 August 2021).
Interests: functional urology; female urology; neuro-urology; oncological urology
Special Issues and Collections in MDPI journals
Botulinum neurotoxins (BoNTs) represent a sophisticated bioweapon with both therapeutic benefits and toxic effects. The high selectivity of BoNTs for nerve endings, their particular ability in inhibiting neurotransmitter release with limited diffusion from the site of injection, and the reversibility of the effect have allowed to use BoNTs for therapeutic purposes, with great benefits in many fields of application. Over time, a better understanding of BoNTs mode of action coming from in vitro and in vivo studies has led to increased therapeutic applications to treat a wide range of diseases. Indeed, different susceptibilities to various types of BoNTs exist between humans and animals and among different animal species, thus making it difficult to transfer the observations obtained on animal models to humans. Currently, there is also growing evidence that BoNTs exhibit biological effects on various human cell types, as the BoNT receptors and intracellular targets are not limited to neurotransmission, but they have been found also in non-neuronal cells. Probably, marked differences exist in how BoNTs bind to, and act on, neuronal vs. non-neuronal cells. To date, epidermal keratinocytes; mesenchymal stem cells from subcutaneous adipose; nasal mucosal cells; urothelial cells; intestinal, prostate and alveolar epithelial, and many other types of cells have been observed to represent targets for BoNTs’ activity.
The aim of this Special Issue, entitled: “Botulinum Toxins: An Application in Humans and Animals,” is to take stock of the situation in the use of BoNTs in both humans and animals, taking into consideration new information on biology, pharmacology, clinical applications, toxicity, and novel indications of these neurotoxins.
Prof. Dr. Antonella Giannantoni
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Botulinum toxins
- mechanism of action
- animal models
- non-neuronal cells
- human diseases